drugset
drugset / Trial / NCT00858572

STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders

NCT00858572 ↗

Phase 1 Completed 31 enrolled Synta Pharmaceuticals Corp.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to characterize the safety and efficacy of STA-9090 (ganetespib) in subjects with hematologic malignancies.

Timeline

Start
2009-03
Primary completion
2011-05
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Ganetespib Small molecule — —

Indications

acute myeloid leukemia chronic myeloid leukemia myelodysplastic syndrome